Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial    crawled time : 01:00    save search
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Published: 2024-02-20 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 twitter stocktwits trandingview |
Health Technology
 | | O: 2.72% H: 0.0% C: -0.8%
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 2.53% H: 0.0% C: 0.0%
ibi311 disease thyroid eye trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Li-Cycle Holdings Corp. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - LICY
Published: 2024-01-03 (Crawled : 01:00) - prnewswire.com
LICY | $0.6731 -5.48% 1.9% 2.4M twitter stocktwits trandingview |
| | O: 0.0% H: 0.92% C: -6.72%
EGRX | $4.58 -3.98% -4.15% 95K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 0.53% C: -7.6%
deadline trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Adobe Inc. Investors to Secure Counsel Before Important December 19 Deadline in Securities Class Action - ADBE
Published: 2023-12-12 (Crawled : 01:00) - prnewswire.com
SLRN | $4.57 -0.65% -0.66% 530K twitter stocktwits trandingview |
| | O: 0.47% H: 0.0% C: -3.78%
DG 4 | $143.16 0.3% -0.08% 1.3M twitter stocktwits trandingview |
Retail Trade
 | | O: -0.12% H: 0.0% C: -1.3%
ADBE A | $477.11 0.89% 0.88% 2M twitter stocktwits trandingview |
Technology Services
 | | O: 0.11% H: 1.28% C: 1.25%
deadline trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages General Motors Company Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GM
Published: 2023-12-12 (Crawled : 01:00) - prnewswire.com
EXFY S | $1.65 6.8% 6.36% 760K twitter stocktwits trandingview |
| | O: 1.75% H: 1.72% C: 0.43%
GM | News 4 d | $45.08 -0.04% 0.22% 15M twitter stocktwits trandingview |
Consumer Durables
 | | O: -0.24% H: 1.22% C: -0.24%
ADBE A | $477.11 0.89% 0.88% 2M twitter stocktwits trandingview |
Technology Services
 | | O: 0.11% H: 1.28% C: 1.25%
company deadline trial
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2023-12-11 (Crawled : 01:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M twitter stocktwits trandingview |
Health Technology
 | | O: 0.75% H: 0.55% C: 0.27%
fabhalta novartis trial results
ROSEN, NATIONAL TRIAL LAWYERS, Encourages LivePerson, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - LPSN
Published: 2023-12-08 (Crawled : 01:00) - prnewswire.com
LICY | $0.6731 -5.48% 1.9% 2.4M twitter stocktwits trandingview |
| | O: 2.24% H: 2.46% C: 0.85%
CHPT 4 | $1.29 -3.73% 0.0% 9.6M twitter stocktwits trandingview |
| | O: -0.89% H: 11.66% C: 5.38%
LPSN S | $0.5034 1.68% 1.65% 2.3M twitter stocktwits trandingview |
Technology Services
 | | O: -0.91% H: 6.73% C: 5.5%
deadline trial
Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023
Published: 2023-11-07 (Crawled : 01:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K twitter stocktwits trandingview |
Health Technology
 | | O: -3.41% H: 3.46% C: 0.25%
kidney nefigard week trial
North America Leads the Clinical Trial Patient Recruitment Services Market with a 50.1% Share in 2022
Published: 2023-10-20 (Crawled : 01:00) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M twitter stocktwits trandingview |
Health Technology
 | | O: -0.35% H: 0.0% C: 0.0%
america services trial market
HE FINAL DEADLINE MONDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Hawaiian Electric Industries, Inc. Investors to Secure Counsel Before Important October 23 Deadline in Securities Class Action - HE
Published: 2023-10-19 (Crawled : 01:00) - prnewswire.com
ACHR | $3.97 -1.0% 0.0% 4M twitter stocktwits trandingview |
| | O: 2.56% H: 4.03% C: -1.73%
HE | $10.88 -0.64% 0.83% 1.5M twitter stocktwits trandingview |
Utilities
 | | O: -0.39% H: 1.03% C: -1.03%
TNDM | $35.12 0.43% 0.43% 1M twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 3.97% C: 1.88%
deadline trial
Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet
Published: 2023-08-18 (Crawled : 01:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K twitter stocktwits trandingview |
Health Technology
 | | O: 4.65% H: 2.16% C: -1.44%
lancet nefigard trial therapeutics results
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia
Published: 2023-07-03 (Crawled : 01:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 1.24% H: 0.0% C: 0.0%
htl0048 agonist schizophrenia trial
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan
Published: 2023-06-21 (Crawled : 01:00) - prnewswire.com
ALBO | $44.15 -0.23% 0.39% 1.2M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
drug japan designation trial odevixibat
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Funko, Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important Deadline in Securities Class Action - FNKO
Published: 2023-06-15 (Crawled : 01:00) - prnewswire.com
HBNC | $12.2 -0.49% -0.49% 160K twitter stocktwits trandingview |
Finance
 | | O: -1.02% H: 4.47% C: 3.18%
FUTU | $63.99 3.33% 3.22% 2.9M twitter stocktwits trandingview |
Technology Services
 | | O: 2.65% H: 1.0% C: -1.16%
FNKO 4 | $6.18 1.15% 1.13% 470K twitter stocktwits trandingview |
Consumer Durables
 | | O: -0.98% H: 0.38% C: -1.22%
deadline trial
FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Eqonex Limited f/k/a Diginex Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 20 Deadline in Securities Class Action - EQOSQ
Published: 2023-06-13 (Crawled : 01:00) - prnewswire.com
BYND 4 | $6.07 0.0% 1.8M twitter stocktwits trandingview |
Consumer Non-Durables
 | | O: 4.43% H: 13.16% C: 7.82%
deadline trial
Chancery Trial Nears On Purple Mattress Poison Pill Challenge – Law360
Published: 2023-04-11 (Crawled : 01:00) - spacfeed.com
DMYS | $10.25 0.0% 54K twitter stocktwits trandingview |
n/a
 | Email alert Add to watchlist
mattress purple trial
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Gemini Earn Program Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Against Gemini Trust Company, LLC, Tyler Winklevoss, and Cameron Winklevoss
Published: 2023-02-07 (Crawled : 01:00) - prnewswire.com
AVYA | $0.021 1280.95% 0 twitter stocktwits trandingview |
Electronic Technology
 | | O: -12.56% H: 0.0% C: 0.0%
program trial trusted trust deadline
NBEV DEADLINE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages NewAge Inc. Investors to Secure Counsel Before Important February 6 Deadline in Securities Class Action Initiated by the Firm - NBEV, NBEVQ
Published: 2023-02-02 (Crawled : 01:00) - prnewswire.com
TTCF | $0.158 -24.76% -32.66% 0 twitter stocktwits trandingview |
Consumer Non-Durables
 | | O: 9.15% H: 10.18% C: 2.99%
SPPI | $1.03 -0.97% 0 twitter stocktwits trandingview |
Health Technology
 | | O: 7.06% H: 1.1% C: -11.45%
trial trusted deadline initiated
AI-based Clinical Trial Solutions For Patient Matching Market Report 2023: Industry to Reach $1.96 Billion by 2030
Published: 2023-01-06 (Crawled : 01:00) - prnewswire.com
MSFT | News 4 | $408.94 0.34% 0.33% 14M twitter stocktwits trandingview |
Technology Services
 | | O: 0.31% H: 1.24% C: 0.87%
solutions report trial market
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA22
Published: 2022-11-02 (Crawled : 01:00) - prnewswire.com
PEN 4 | $206.15 0.22% 0.0% 340K twitter stocktwits trandingview |
Health Technology
 | | O: -0.46% H: 1.54% C: -2.31%
viva22 trial results
Angel Pharmaceuticals Announces Approval of IND Application for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
Published: 2022-09-27 (Crawled : 01:00) - prnewswire.com
CRVS | $1.58 3.27% 3.16% 91K twitter stocktwits trandingview |
Health Technology
 | | O: -1.97% H: 4.21% C: -0.38%
cd73 pharmaceuticals application trial approval china phase 1
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services
BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services
MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.